Indeed, Simmons et al. [104] made us of mTORi (rapamycin) and HDACi (MS-275/entinostat) inhibitors in myeloma, reducing MYC protein stability and causing a significant anti-tumor effect. The gene discussed is MYC; the disease is plasma cell myeloma.